GPX4 and diffuse large B-cell lymphoma: All DLBCL lines demonstrated a steep, dose-dependent decline in viability within the low nanomolar to sub-micromolar range following GPX4 inhibition, with no consistent difference in sensitivity between ABC and GCB subtypes (Fig. 2A–C).